Coppieters K - Search Results

1

CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor.

Pagni PP, Wolf A, Lo Conte M, Yeh R, Fu G, Liu F, von Herrath M, Coppieters K. Pagni PP, et al. Among authors: coppieters k. Diabetologia. 2019 Sep;62(9):1727-1729. doi: 10.1007/s00125-019-4893-2. Epub 2019 May 17. Diabetologia. 2019. PMID: 31101931 No abstract available.

2

Clinical potential of antigen-specific therapies in type 1 diabetes.

Coppieters KT, Sehested Hansen B, von Herrath MG. Coppieters KT, et al. Rev Diabet Stud. 2012 Winter;9(4):328-37. doi: 10.1900/RDS.2012.9.328. Epub 2012 Dec 28. Rev Diabet Stud. 2012. PMID: 23804270 Free PMC article. Review.

3

The type 1 diabetes signature: hardwired to trigger inflammation?

Coppieters KT, von Herrath MG. Coppieters KT, et al. Diabetes. 2014 Nov;63(11):3581-3. doi: 10.2337/db14-0824. Diabetes. 2014. PMID: 25342729 Free PMC article. No abstract available.

4

The Hsp60 peptide p277 enhances anti-CD3 mediated diabetes remission in non-obese diabetic mice.

Sarikonda G, Sachithanantham S, Miller JF, Pagni PP, Coppieters KT, von Herrath M. Sarikonda G, et al. J Autoimmun. 2015 May;59:61-6. doi: 10.1016/j.jaut.2015.02.003. Epub 2015 Mar 13. J Autoimmun. 2015. PMID: 25772283

5

Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse.

Pham MN, Gibson C, Rydén AK, Perdue N, Boursalian TE, Pagni PP, Coppieters K, Skonberg C, Porsgaard T, von Herrath M, Vela JL. Pham MN, et al. Among authors: coppieters k. Clin Immunol. 2016 Mar;164:28-33. doi: 10.1016/j.clim.2016.01.013. Epub 2016 Jan 25. Clin Immunol. 2016. PMID: 26821303

6

Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes.

Rydén AK, Perdue NR, Pagni PP, Gibson CB, Ratliff SS, Kirk RK, Friesen TJ, Haase C, Coppieters K, von Herrath MG, Boursalian TE. Rydén AK, et al. Among authors: coppieters k. J Autoimmun. 2017 Nov;84:65-74. doi: 10.1016/j.jaut.2017.07.006. Epub 2017 Jul 12. J Autoimmun. 2017. PMID: 28711285

7

Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy.

Coppieters K, von Herrath M. Coppieters K, et al. Cell Metab. 2017 Oct 3;26(4):595-597. doi: 10.1016/j.cmet.2017.09.016. Cell Metab. 2017. PMID: 28978425 Free article.

8

The Development of Immunotherapy Strategies for the Treatment of Type 1 Diabetes.

Coppieters K, von Herrath M. Coppieters K, et al. Front Med (Lausanne). 2018 Oct 9;5:283. doi: 10.3389/fmed.2018.00283. eCollection 2018. Front Med (Lausanne). 2018. PMID: 30356664 Free PMC article. Review.

9

Trials in type 1 diabetes: Antigen-specific therapies.

Coppieters KT, Harrison LC, von Herrath MG. Coppieters KT, et al. Clin Immunol. 2013 Dec;149(3):345-55. doi: 10.1016/j.clim.2013.02.002. Epub 2013 Feb 15. Clin Immunol. 2013. PMID: 23490422 Free PMC article. Review.

10

Non-antigenic and antigenic interventions in type 1 diabetes.

Rydén AK, Wesley JD, Coppieters KT, Von Herrath MG. Rydén AK, et al. Among authors: coppieters kt. Hum Vaccin Immunother. 2014;10(4):838-46. doi: 10.4161/hv.26890. Epub 2013 Oct 28. Hum Vaccin Immunother. 2014. PMID: 24165565 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters